Chinese medicine composition for treating liver fibrosis and portal vein hypertension and its preparation method

A technology for liver fibrosis and portal hypertension, applied in the field of traditional Chinese medicine compositions and their preparation, can solve the problems of simple action, inability to effectively block the pathological process, limited action and the like

Inactive Publication Date: 2009-10-07
BEIJING KYY BIOSCI
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most of these drugs only play a role in a certain stage or a certain link of the pathological process of liver fibrosis, and are aimed at the complex pathological process of liver fibrosis with chronic liver injury, especially the coexistence of inflammation, necrosis, and hyperplasia (hepatocytes, collagen fibers) In general, the effects of these drugs are obviously limited, but for chronic hepatitis, especially early fibrosis, it seems to have a simple effect, and effectively blocking the pathological process at this stage is more important than reversing the treatment of liver fibrosis
[0003] In recent years, many kinds of Chinese patent medicines have been developed for liver fibrosis by invigorating the spleen and removing dampness, promoting blood circulation and removing blood stasis. They can alleviate the symptoms of liver fibrosis at a certain stage, but they cannot effectively block the pathological process

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chinese medicine composition for treating liver fibrosis and portal vein hypertension and its preparation method
  • Chinese medicine composition for treating liver fibrosis and portal vein hypertension and its preparation method
  • Chinese medicine composition for treating liver fibrosis and portal vein hypertension and its preparation method

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0015] Experimental Example 1 Screening of Salvianolic Acid and Glycyrrhizic Acid Compatibility Ratio

[0016] Salvianolic acid salt and glycyrrhizic acid salt were designed for single use and compatibility according to the effective level of primary screening, and four groups A, B, C, and D were formed, and the CCl with multi-index design 4 - Drug efficacy screening of olive oil rat liver injury model.

[0017] A licorice monoamine salt 10g plus salvianolic acid salt 10g

[0018] B glycyrrhizin diamine salt 10g plus salvianolic acid salt 10g

[0019] C glycyrrhizin monoamine salt 20g

[0020] D Glycyrrhizin Diamine Salt 20g

[0021] The result is as follows:

[0022] 1. Body weight change and coefficient of liver and spleen organs

[0023] (1) to CCl 4 Effects on Inducing Rat Growth Curves:

[0024] The experimental data are summarized in Table 1, and the results show that: ① There was no significant difference in the body weight of each group after randomization befor...

experiment example 2

[0122] Experimental example 2 Study on the characteristics of salvianolic acid and glycyrrhizic acid and the curative effect of compatibility

[0123] 1. Evaluation of curative effect of salvianolic acid and glycyrrhizic acid combined with prescription of the present invention on rats with hepatic fibrosis

[0124] (1) Effect on the liver coefficient

[0125] Compared with the normal group, the liver coefficient (liver weight g / rat weight 100g) in the model group increased by 100.08% (P<0.01), in the colchicine group increased by 84.01% (P<0.01), and in the salvianolic acid group increased increased by 78.47% (P<0.01), glycyrrhizic acid group increased by 93.36 (P<0.01), and combination group increased by 73.23% (P<0.01, see Table 15);

[0126] Compared with the model group, the colchicine group decreased by 8.03%, the salvianolic acid group decreased by 10.80%, the glycyrrhizic acid group decreased by 3.36%, and the combination group decreased by 13.42% (P<0.05);

[0127] C...

experiment example 3

[0230] Experimental Example 3 Effects of Salvianolic Acid and Glycyrrhizic Acid Compatibility of the Present Invention on In Vivo Portal Vein Pressure and Isolated Portal Vein Reactivity Changes

[0231] After the combination of salvianolic acid and glycyrrhizic acid, compared with the single use of the two drugs, the new effect is to significantly reduce the portal pressure of liver fibrosis, which is a new breakthrough discovery. This effect has a very important clinical value for chronic hepatitis, liver fibrosis, and portal hypertension associated with liver cirrhosis, and fills the gap in the drug treatment of this pathological state.

[0232] 1. Compatibility compound to CCl 4 Effects of Induced Hepatic Fibrosis on Portal Pressure in Rats in Vivo:

[0233] The experimental data are summarized in Table 18, and the results show that: ①The portal venous pressure (PVP, mmHg) of the modeling group was significantly higher than that of the normal control group (P<0.01); <0.0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a traditional Chinese medicine composition for liver fibrosis and portal hypertension. The composition is prepared by taking 1 weight part of licorice extract and 2-7 weight parts of salvia miltiorrhiza as raw materials. The preparation method is to take Danshen and grind it, extract it with hot water; combine the extracts, freeze, and filter; pass the filtrate through a macroporous adsorption resin column, wash the column with water, discard the eluent; then elute with 40% ethanol, and collect the eluate; Concentrate under reduced pressure to dryness to obtain the dry extract of Danshen; mix the dry extract of Danshen and licorice extract, add conventional auxiliary materials, and prepare a clinically acceptable dosage form. In the present invention, glycyrrhizic acid salt and salvianolic acid salt can also be prepared directly as raw materials. The composition of the present invention can significantly reduce the portal vein pressure of liver fibrosis, which has very important clinical value for portal hypertension associated with chronic hepatitis, liver fibrosis and liver cirrhosis, and fills the gap in drug treatment of this pathological state. blank.

Description

technical field [0001] The invention relates to a traditional Chinese medicine composition and a preparation method thereof, in particular to a traditional Chinese medicine composition for treating liver fibrosis and portal hypertension and a preparation method thereof. Background technique [0002] At present, the focus of drug research on the treatment of liver fibrosis is to reverse liver fibrosis and improve liver function damage caused by liver fibrosis. Research on extracts has also yielded impressive results. However, most of these drugs only play a role in a certain stage or a certain link of the pathological process of liver fibrosis, and are aimed at the complex pathological process of liver fibrosis with chronic liver injury, especially the coexistence of inflammation, necrosis, and hyperplasia (hepatocytes, collagen fibers) In general, the effects of these drugs are obviously limited, but for chronic hepatitis, especially early fibrosis, it seems to have a simpl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/53A61K36/484A61K9/00A61P1/16
Inventor 李澎涛秦森邦陆辉蔡大勇唐卉玲贺勇
Owner BEIJING KYY BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap